Aktienanalyse zu Omeros Corp (OMER)OMEROmeros Corp

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Omeros Corp is a good buy right now due to its current price of $16.57, which is significantly below the analyst price target of $33, indicating a potential upside of about 99%. Additionally, the company has shown strong gross margins of 97.20% in Q2 2026, reflecting efficient operations despite recent challenges. The main risk is the recent EMA rejection of its drug, which could affect future revenue streams, but analysts believe this selloff is overdone, providing a favorable entry point.

7 analysts cover OMER: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 43.67.